Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways

Clinical Immunology

Volumn 127, Issue 3, 2008, Pages 322-329

  Yu, Qi T ^a   Saruta, Masayuki ^a   Papadakis, Konstantinos A ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Crohn's Disease; Inflammatory Bowel diseases; Low Fc receptor binding anti CD3 antibodies; Mucosal T Lymphocytes; Ulcerative colitis; Visilizumab

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CASPASE 3; CASPASE 8; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; INFLIXIMAB; LIPOCORTIN 5; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PREDNISONE; STEROID; VISILIZUMAB;

ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INTESTINE MUCOSA; LAMINA PROPRIA; MALE; MUCOSAL IMMUNITY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 8; CELLS, CULTURED; COLITIS, ULCERATIVE; ENZYME INHIBITORS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MUCOUS MEMBRANE; T-LYMPHOCYTES;

EID: 45249104849     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.02.009     Document Type: Article

References (31)

1. Geboes K., and De Hertogh G. Indeterminate colitis. Inflammatory Bowel Dis. 9 5 (2003) 324-331
2. Ina K., Itoh J., Fukushima K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163 2 (1999) 1081-1090
3. Bu P., Keshavarzian A., Stone D.D., et al. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J. Immunol. 166 10 (2001) 6399-6403
4. Sturm A., Mohr S., and Fiocchi C. Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology 122 5 (2002) 1334-1345
5. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.[see comment]. Gut 50 2 (2002) 206-211
6. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.[see comment]. Gastroenterology 124 7 (2003) 1774-1785
7. Doering J., Begue B., Lentze M.J., et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.[see comment]. Gut 53 11 (2004) 1632-1638
8. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.[see comment]. J. Clin. Invest 111 8 (2003) 1133-1145
9. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. [see comment]. N. Eng. J. Med. 330 26 (1994) 1841-1845
10. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Eng. J. Med. 353 23 (2005) 2462-2476
11. Plevy S.E., Salzberg B., van Assche G., et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe, steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 126 (2004) A-75 Abstr. 579
12. Cole M.S., Stellrecht K.E., Shi J.D., et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68 4 (1999) 563-571
13. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 8 (2002) 2712-2719
14. Cole M.S., Anasetti C., and Tso J.Y. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J. Immunol. 159 7 (1997) 3613-3621
15. Hsu D.H., Shi J.D., Homola M., et al. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation 68 4 (1999) 545-554
16. Parleviet K.J., Jonker M., ten Berge R.J., et al. Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 50 5 (1990) 889-892
17. Carpenter P.A., Pavlovic S., Tso J.Y., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165 11 (2000) 6205-6213
18. Yu X.Z., Levin S.D., Madrenas J., and Anasetti C. Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J. Immunol. 172 3 (2004) 1437-1443
19. Papadakis K.A., Zhu D., Prehn J.L., et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J. Immunol. 174 8 (2005) 4985-4990
20. Woo M., Hakem R., Soengas M.S., et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12 6 (1998) 806-819
21. Sabbagh L., Kaech S.M., Bourbonniere M., et al. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J. Immunol. 173 9 (2004) 5425-5433
22. Salmena L., Lemmers B., Hakem A., et al. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev. 17 7 (2003) 883-895
23. Vexler V., and Woo J. Antibody treatment of ulcerative colitis. Drug Discov. Today: Therapeutic Strategies 3 3 (2006) 353-360
24. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.[see comment]. N. Eng. J. Med. 346 22 (2002) 1692-1698
25. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9 9 (2003) 1202-1208.
26. Kohm A.P., Williams J.S., Bickford A.L., et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174 8 (2005) 4525-4534
27. Sturm A., Leite A.Z., Danese S., et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.[see comment]. Gut 53 11 (2004) 1624-1631
28. Peppelenbosch M.P., and van Deventer S.J. T cell apoptosis and inflammatory bowel disease.[comment]. Gut 53 11 (2004) 1556-1558
29. Hommes D., Targan S., Baumgart D.C., Dignass A.U., Mayer L., and Lowder J.N. A phase I study: Visilizumab therapy in Crohn's disease (CD) patients refractory to infliximab treatment. Gastroenterology 130 (2006) 769 A-111
30. Brimnes J., Allez M., Dotan I., Shao L., Nakazawa A., and Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. 174 9 (2005) 5814-5822
31. Zhang L., Sho M., Su M., Lowder J., Woo J., and Law D. Visilizumab treatment promotes morphological recovery, reduces inflammatory markers and affects T cell subsets in mucosa of ulcerative colitis patients. Gastroenterology 130 (2006) S1332 A-204